BCAX files Form 144 to sell 13,555 shares

BCAX submitted a Form 144 reporting a proposed sale of 13,555 common shares to be sold on 03/03/2026 following an exercise of stock options for cash through the issuer.

Accepted by SEC EDGAR 03/03/2026 - 04:48 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

BCAX submitted a Form 144 reporting a proposed sale of 13,555 common shares to be sold on 03/03/2026 following an exercise of stock options for cash through the issuer.

The filing also discloses prior sales by the reporting person: 9,200 shares on 12/22/2025$168,491.56 and 1,882 shares on 01/22/2026$34,162.44.

Insights

Equity Capital Markets Analyst

Notice of an issuer-directed sale following option exercise; prior small disposals are disclosed.

The filing lists a proposed resale of 13,555 common shares on 03/03/2026exercise of stock options with cash proceeds routed through the issuer. Cash-flow treatment is explicitly stated as Cash.

Prior dispositions include 9,200 shares on 12/22/20251,882 shares on 01/22/2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does BCAX's Form 144 disclose about the planned sale?

It discloses a proposed sale of 13,555 common shares on 03/03/2026exercise of stock options. The filing states the sale method as issuer-directed for cash consideration.

Who sold shares previously according to the Form 144 for BCAX?

The filing lists prior sales by the reporting person of 9,200 shares on 12/22/20251,882 shares on 01/22/2026

How much cash was reported for the previous BCAX sales?

Proceeds shown were $168,491.56 for the 9,200-share sale and $34,162.44 for the 1,882-share sale. These amounts appear directly beside each dated transaction.

Does the Form 144 show how the 13,555 shares will be sold?

Yes. The filing states the shares are to be sold following an exercise of stock options and indicates the transaction is through the issuer with proceeds in cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002034668
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Bicara Therapeutics Inc.
SEC File Number	001-42271
Address of Issuer	116 HUNTINGTON AVENUE SUITE 703 BOSTON MASSACHUSETTS 02116
Phone	617-468-4219
Name of Person for Whose Account the Securities are To Be Sold	Hyep Ivan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	13555	246909.75	54781950	03/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/03/2026	Exercise of stock options	Issuer			13555	03/03/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ivan Hyep 116 HUNTINGTON AVENUE SUITE 703 Boston MA 02116	Common	12/22/2025	9200	168491.56
Ivan Hyep 116 HUNTINGTON AVENUE SUITE 703 Boston MA 02116	Common	01/22/2026	1882	34162.44

144: Remarks and Signature

Remarks
Date of Notice	03/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/13/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc., as attorney-in-fact for Ivan Hyep
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)